PharmaJet inks MoU with Egypt’s UPA and EVA Pharma to offer needle-free delivery for routine immunization
The agreement includes plans for distribution, technology transfer, local manufacturing, new pharmaceutical product development
The agreement includes plans for distribution, technology transfer, local manufacturing, new pharmaceutical product development
Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases
Teva will leverage Honeywell’s ‘Energy as a Service’ (EaaS) model
The new facility will provide an important boost to vaccine capacity in Africa
Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
Subscribe To Our Newsletter & Stay Updated